A5084508530- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- Immune Cell Function and Interaction
- Peptidase Inhibition and Analysis
- Hemoglobinopathies and Related Disorders
- Biosimilars and Bioanalytical Methods
- Viral Infectious Diseases and Gene Expression in Insects
- Acute Lymphoblastic Leukemia research
- T-cell and B-cell Immunology
- Cancer Immunotherapy and Biomarkers
- Cancer-related gene regulation
- Hepatitis B Virus Studies
- Testicular diseases and treatments
- RNA modifications and cancer
- Neuroblastoma Research and Treatments
- RNA Interference and Gene Delivery
- Colorectal Cancer Treatments and Studies
- Integrated Circuits and Semiconductor Failure Analysis
- Neurofibromatosis and Schwannoma Cases
- Xenotransplantation and immune response
- Cancer Treatment and Pharmacology
- Antimicrobial Peptides and Activities
- HIV, Drug Use, Sexual Risk
- Hepatitis C virus research
National Cancer Institute
2011-2024
National Institutes of Health
2012-2024
Center for Cancer Research
2012-2024
National Heart Lung and Blood Institute
2022-2024
Johns Hopkins University
2022
Pediatrics and Genetics
2022
University of Virginia
2018
National Cancer Institute
2016
Harvard University Press
1993
Although tumors naturally prime adaptive immune responses, tolerance may limit the capacity to control progression and can compromise effectiveness of immune-based therapies for cancer. Post-proline cleaving enzymes (PPCE) modulate protein function through N-terminal dipeptide cleavage inhibition these has been shown have anti-tumor activity. We investigated mechanism by which Val-boroPro, a boronic that inhibits post-proline enzymes, mediates tumor regression tested whether this agent could...
Summary Diamond–Blackfan anaemia (DBA) is a rare, inherited bone marrow failure syndrome with ribosomal defect causing slowed globin chain production normal haem synthesis, an overabundance of reactive iron/haem and erythroid‐specific cellular toxicity. Eltrombopag, non‐peptide thrombopoietin receptor agonist, potent intracellular iron chelator induced robust durable response in RPS19 ‐mutated DBA patient on another trial. We hypothesized eltrombopag would improve RBC patients. conducted...
Hepatitis virus infections are common among injecting drug users. Syringes containing hepatitis B (HBV) DNA and C (HCV) RNA were identified by polymerase chain reaction (PCR); syringes antibodies to HBV core antigen HCV EIA. Syringe use was simulated determine the sensitivity of these assays. The mean limits for PCR 0.082 µL blood 0.185 HCV; EIA 0.023 ILL HCV. testing 681 returned needle exchange program in New Haven, Connecticut, revealed a decline from 7.8% HBV-positive at program's outset...
Multimodality therapy consisting of surgery, chemotherapy, and radiation will fail in approximately 40% patients with pediatric sarcomas result substantial long-term morbidity those who are cured. Immunotherapeutic regimens for the treatment solid tumors typically generate antigen-specific responses too weak to overcome considerable tumor burden suppressive mechanisms need adjuvant assistance. Previous work suggests that inhibitors DASH (dipeptidyl peptidase IV activity and/or structural...
Severe combined immunodeficient (SCID) mice were transplanted with different human fetal organs (SCID-hu mice), including thymus, liver, spleen, and omentum, the serum levels of IgM, IgG, IgE, IgA measured. In all SCID-hu significant (up to 590 ng/ml) IgM detected, irrespective transplanted. contrast, IgG was present 530 only when thymus together indicating that presence T cell is a prerequisite for in vivo isotypes switching by B cells mice. Additional transplantation spleen did not...
Abstract Tumor-targeted vaccines represent a strategy to enhance the graft-versus-leukemia effect after allogeneic blood and marrow transplantation (BMT). We have previously shown that graft-versus-host disease (GVHD) can negatively impact quantitative responses vaccines. Using minor histocompatibility Ag–mismatched BMT (B6→B6 × C3H.SW) followed by adoptive transfer of HY-specific T cells HY-expressing dendritic cells, we assessed whether GVHD induced donor lymphocyte infusion (DLI) affects...
<h3>Background</h3> Natural killer (NK) cells play a crucial role in immunosurveillance and antitumor immunity via detection elimination of virally-infected or neoplastic cells.<sup>1 2</sup> With low risk graft-versus-host disease following allogenic adoptive transfer potent killing capabilities, NK have unique potentials for cell-based therapies as shown recent proof-of-concept clinical trials, particularly the introduction targeted chimeric antigen receptors (CAR).<sup>3 4</sup> Efforts...
2553 Background: FAK transduces signaling from integrins and growth factors to modulate tumor cell invasion, proliferation, survival. PF-562271, a potent inhibitor, is under development as an anticancer agent. Preclinical studies demonstrated that PF-562271 inhibitor of its primary metabolizing enzyme, CYP3A. PK effect on CYP3A were investigated in dose-escalation trial patients with nonhematologic malignancies. Methods: Escalating doses administered orally total 67 twice day (BID) or once...
Abstract Graft versus leukemia (GVL) responses contribute to the curative potential of allogeneic blood or marrow transplantation (alloBMT) but can be associated with graft host disease (GVHD). Tumor-targeted vaccines have enhance potency and specificity GVL, we shown that GVHD limit responses. Using a minor histocompatibility-mismatched BMT (B6 -&gt;C3H.SW) donor lymphocyte infusions (DLI), examined mechanism reduced vaccine The proliferative capacity, persistence survival...
We present an 18-year-old male patient who presented with a 16 cm testicular tumor alongside multiple lesions in the lungs, right pelvis involvement of ischio/pubic bone, and enlarged pelvic lymph nodes on imaging, suspicious for metastatic disease. Histologic immunohistochemical examinations revealed embryonic type neuroectodermal (somatic-type malignancy, 10%) arising malignant mixed germ cell composed teratoma (50%), embryonal carcinoma (10%) yolk sac (30%). After treatment chemotherapy...